 Hepatitis B virus HBV infection is the major risk factor for HCC development in China. Some retrospective studies have shown that lamivudine or entecavir treatment for HBV-related HCC patients can effectively reduce the HCC recurrence rate and increase the survival rate after hepatectomy. However, which drug has more efficacy has not been addressed. 